The Crohn’s disease (CD)
market is currently very dynamic, with novel biologic therapies on the horizon.
These compounds will challenge the current biologics in an attempt to dislodge
the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion
of the CD therapeutics market. If their promising safety and efficacy profiles
translate to clinical practice once they enter the market, their launch will be
to the detriment of the existing market leaders, Remicade (infliximab) and
Humira (adalimumab).The loss of patent protection of the anti-TNF marketed
brands will allow for the emergence of biosimilars, such as Hospira’s Inflectra
(infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and
the emerging markets of China and India will also play a key role in driving
growth in the long term, with each market forecast to post positive Compound
Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated
strong uptake of Remicade over the forecast period.

For the treatment of CD,
Indian physicians rely heavily on non-pharmacological methods, such as dietary
recommendations, and for pharmacologic therapy, they use generic products
within the corticosteroids and 5-ASAs. Publisher’s physician survey showed that
these drugs are the mainstay of treatment for mild to moderate CD in India, as
well as at earlier lines of therapy for severe disease. While Indian physicians
commonly prescribe domestic generics and biosimilars, our primary research
revealed that biosimilars were not readily available to those with CD.

Market
Research Reports, Inc.
is the world's leading source for market research reports and market data. We
provide you with the latest market research reports on global markets, key
industries, leading companies, new products and latest industry analysis &
trends.